Objectives: The aim of this investigation was to test whether the administration of atrial
natriuretic peptide (ANP) has cardioprotective effects against ischaemic and reperfusion …

BACKGROUND: Atrial natriuretic peptide (ANP), a stimulator of particulate guanylate
cyclase, has been found to protect against reoxygenation-induced hypercontracture in …

We investigated whether atrial natriuretic peptide (ANP) given just prior to reperfusion
reduces infarction in rabbit hearts and whether protection is related to activation of protein …

The aim of the present study was to examine the effects of atrial natriuretic peptide (ANP) on
the responses to coronary artery occlusion. In chloralose-urethane anaesthetised mongrel …

Acute coronary artery occlusion triggers the release of atrial natriuretic peptide (ANP) from
the heart. ANP affects vasodilation, natriuresis, and inflammation, but the integrated …

OBJECTIVE: Human atrial natriuretic peptide has recently become known not only as a
heart failure drug but also for myocardial protection. We investigated its direct myocardial …

Atrial natriuretic peptide (ANP) is a member of the natriuretic peptide family that exerts
various biological effects via acting on the receptor-guanylyl cyclase system, increasing the …

Objectives Alpha-human atrial natriuretic peptide (alpha-hANP) has been used to treat
patients with heart failure due to its natriuretic and vasodilatory activities. Recent reports …

Carperitide, a synthetic alpha-human atrial natriuretic peptide (ANP) is a newly developed
drug for the treatment of heart failure. However, effects of carperitide on susceptibility to …

BACKGROUND It has been shown that atrial natriuretic peptide (ANP), an endogenous
vasodilator, dilates coronary arteries and decreases coronary vascular resistance. The …